NYSE American - Nasdaq Real Time Price • USD
NovaBay Pharmaceuticals, Inc. (NBY)
As of 12:36 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 2 | 2 |
Avg. Estimate | -0.15 | -0.09 | -0.27 | 0.02 |
Low Estimate | -0.25 | -0.14 | -0.41 | -0.02 |
High Estimate | -0.05 | -0.04 | -0.13 | 0.07 |
Year Ago EPS | -0.85 | -1.27 | -3.96 | -0.27 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 2 | 2 |
Avg. Estimate | 3.28M | 3.58M | 14.8M | 19.29M |
Low Estimate | 3M | 3M | 13.5M | 17M |
High Estimate | 3.56M | 4.15M | 16.1M | 21.57M |
Year Ago Sales | 3.2M | -- | 14.73M | 14.8M |
Sales Growth (year/est) | 2.50% | -- | 0.50% | 30.30% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.91 | -0.55 | -0.4 | -0.3 |
EPS Actual | -0.85 | -1.27 | -0.37 | -1.33 |
Difference | 0.06 | -0.72 | 0.03 | -1.03 |
Surprise % | 6.60% | -130.90% | 7.50% | -343.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.15 | -0.09 | -0.27 | 0.02 |
7 Days Ago | -0.25 | -0.14 | -0.41 | 0.07 |
30 Days Ago | -0.2 | -0.2 | -0.73 | 0.01 |
60 Days Ago | -0.2 | -0.2 | -0.73 | 0.01 |
90 Days Ago | -0.22 | -0.18 | -0.64 | 0.01 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | 1 | 1 | -- |
Up Last 30 Days | 1 | 1 | 1 | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | NBY | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 82.40% | -- | -- | 0.80% |
Next Qtr. | 92.90% | -- | -- | 9.60% |
Current Year | 93.20% | -- | -- | 4.50% |
Next Year | 107.40% | -- | -- | 13.30% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
Earnings
Upgrades & Downgrades
Maintains | Ladenburg Thalmann: Buy to Buy | 8/11/2023 |
Related Tickers
ELAB Elevai Labs, Inc.
0.5751
-0.84%
GRTX Galera Therapeutics, Inc.
0.1854
-0.33%
CLNN Clene Inc.
0.3282
-0.52%
BRTX BioRestorative Therapies, Inc.
1.3500
-4.29%
AMPE Ampio Pharmaceuticals, Inc.
0.3600
+48.76%
GRI GRI Bio, Inc.
0.5178
+0.47%
ALLR Allarity Therapeutics, Inc.
1.5001
-2.59%
SPRC SciSparc Ltd.
1.2500
-3.10%
RNAZ TransCode Therapeutics, Inc.
0.4900
-2.34%
SNGX Soligenix, Inc.
0.4123
-5.28%